Member Info for lofas

Re:Modi-1…careful choice of wording ..old data good progress not exited. Looks below expectation.

Deals happen all the time. Last AZ tells us that billions exchange hands when there is something worth buying.

When status of share price is based on maybe if hope possible and other meaningless wishful thinking words then outcome is clear, that what I meant.

Hope, might & possible can only push SP down or sideways …get some sleep.

Every little helps , DNA based vaccine with less than 10% of complete response and on average efficacy increment from 18% to 30% in comparison to Keytruda on its own. Will be interesting go to compare to SC results when published.

Rat, makes perfect sense , we must be getting RNS 2moro or in the very near future. Due to the magnitude of the event and the slot allocation it wouldn’t be unreasonable to expect top mark results which may be unique to Scancell game changer technology.

…yet, RNS Monday is more the sensible logical expectation. ATVB

Although every patient is the whole world, statistically it may not be significant hence within the boundaries of content which was already communicated.

10p price tag. It will continue to busk in that region if there are no game changer updates. Why we always debate the obvious, no commercialisation takeover or other major news and the SP will go down or sideways.

Berms ,thanks for your feedback…impatiently waiting for some game changer updates.

Waste of RNS. So excited from this non stop BS updates from management.

As mentioned “ without major news underpinning the larger MarketCap.” Share price will stay where it is and all calls for being undervalued can be can be send to the nearest bin.

All PR is pointing to major update. It would be unthinkable otherwise.

Moonparty, interesting point, the timing of the interview. The content was a good summary of where we are at present, no additional news, as this will require RNS. All we can do is read between the lines and have our own interpretation. As mentioned before good news can bare some delay as we are all sure that the next update have the potential to lift market value to a sensible level.

Bottom line,

If SC are not happy with their AIM valuation, then, they can do something about it….or ignore.

What’s the Nasdaq incentive?

It will require a massive consolidation (mathematical exercise ) which in theory not cause any change in fortune to PI. Possible M&A is not going to be impacted from this move. As far as open SC to the US market, yes it may attract additional investors, however that should also be the case if the ongoing trial outcome is positive or above.

Always was in the opinion that bad news will be broadcasted without delay, whereas good news can bare some delay to gain better position with interested parties ,and/or ongoing negotiations.

Thanks Berms. I thought prospective patient suggested they are on standby hence my assumption.

No worries, one direction = deal for the platform and/or the entire tool box.

All we know is that outcome remains in line with expectations and there are some Twits that people in the know are encouraged by the results. We also know that trial is sold out, 168 patients across the four cohort. Add to that the complete silent on the wire it is all pointing to one direction. Good luck to all folks involved with Scancell.